Xynomic Buys Rights to Boehringer's Phase II Ready mTORC1/2 Inhibitor

 
• By Sten Stovall
  
Handshake
BI 860585 is a potent and selective ATP-competitive mTOR serine/threonine kinase inhibitor. • Source: Shutterstock

More from Business

More from Scrip